Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
$39.47
+1.4%
$41.96
$33.82
$49.07
$26.37B1.214.34 million shs1.36 million shs
Lazard, Inc. stock logo
LAZ
Lazard
$45.21
+3.2%
$49.75
$35.56
$61.14
$5.10B1.41886,275 shs739,024 shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.65
+1.8%
$34.43
$26.32
$170.47
$10.69B1.866.91 million shs8.44 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
-0.69%-3.09%-10.44%-7.92%+6.08%
Lazard, Inc. stock logo
LAZ
Lazard
+1.26%-6.28%-12.69%-14.80%+7.27%
Moderna, Inc. stock logo
MRNA
Moderna
-4.20%-19.76%-12.27%-34.68%-74.28%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
4.9809 of 5 stars
3.34.05.03.54.02.52.5
Lazard, Inc. stock logo
LAZ
Lazard
4.3431 of 5 stars
3.01.02.52.31.81.73.1
Moderna, Inc. stock logo
MRNA
Moderna
4.409 of 5 stars
4.01.00.04.62.42.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
2.56
Moderate Buy$47.5020.34% Upside
Lazard, Inc. stock logo
LAZ
Lazard
2.00
Hold$54.1719.81% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.00113.38% Upside

Current Analyst Ratings Breakdown

Latest MRNA, LAZ, and FITB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2025
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.00
3/24/2025
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$52.00 ➝ $43.00
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/13/2025
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$57.00 ➝ $52.00
3/13/2025
Lazard, Inc. stock logo
LAZ
Lazard
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$63.00 ➝ $56.00
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
3/5/2025
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$51.00 ➝ $51.00
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
$8.25B3.20$4.04 per share9.78$26.14 per share1.51
Lazard, Inc. stock logo
LAZ
Lazard
$3.09B1.65$4.22 per share10.71$4.28 per share10.56
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.34N/AN/A$28.33 per share0.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
$2.31B$3.1412.579.601.4217.43%14.10%1.16%4/17/2025 (Estimated)
Lazard, Inc. stock logo
LAZ
Lazard
$279.91M$2.6617.008.93N/A8.98%44.58%5.26%4/24/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)

Latest MRNA, LAZ, and FITB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
Lazard, Inc. stock logo
LAZ
Lazard
$0.65N/AN/AN/A$698.39 millionN/A
4/17/2025N/A
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
$0.72N/AN/AN/A$2.17 billionN/A
1/30/2025Q4 2024
Lazard, Inc. stock logo
LAZ
Lazard
$0.69$0.78+$0.09$0.80$793.53 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
$1.483.75%+8.10%47.13%14 Years
Lazard, Inc. stock logo
LAZ
Lazard
$2.004.42%+2.08%75.19%N/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest MRNA, LAZ, and FITB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/20/2025
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
quarterly$0.373.74%3/31/20253/31/20254/15/2025
1/29/2025
Lazard, Inc. stock logo
LAZ
Lazard
quarterly$0.503.82%2/10/20252/10/20252/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
0.82
0.80
0.80
Lazard, Inc. stock logo
LAZ
Lazard
2.72
2.24
2.24
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62

Institutional Ownership

CompanyInstitutional Ownership
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
83.79%
Lazard, Inc. stock logo
LAZ
Lazard
54.80%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
0.53%
Lazard, Inc. stock logo
LAZ
Lazard
3.86%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fifth Third Bancorp stock logo
FITB
Fifth Third Bancorp
18,724668.10 million667.19 millionOptionable
Lazard, Inc. stock logo
LAZ
Lazard
3,400112.77 million108.41 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable

Recent News About These Companies

Moderna, Inc. stock logo
Moderna (NASDAQ:MRNA) Shares Gap Down - What's Next?
Moderna put volume heavy and directionally bearish
Moderna (MRNA) Stock Trades Down, Here Is Why
Moderna, Rocket, Hut 8: Market Minute

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Fifth Third Bancorp stock logo

Fifth Third Bancorp NASDAQ:FITB

$39.47 +0.54 (+1.39%)
As of 02:46 PM Eastern

Fifth Third Bancorp operates as the bank holding company for Fifth Third Bank, National Association that engages in the provision of a range of financial products and services in the United States. It operates through three segments: Commercial Banking, Consumer and Small Business Banking, and Wealth and Asset Management. The Commercial Banking segment offers credit intermediation, cash management, and financial services; lending and depository products; and cash management, foreign exchange and international trade finance, derivatives and capital markets services, asset-based lending, real estate finance, public finance, commercial leasing, and syndicated finance for business, government, and professional customers. The Consumer and Small Banking segment provides a range of deposit and loan products to individuals and small businesses; home equity loans and lines of credit; credit cards; and cash management services. This segment also engages in the residential mortgage that include origination, retention and servicing of residential mortgage loans, sales and securitizations of loans, and hedging activities; indirect lending, including extending loans to consumers through automobile dealers, motorcycle dealers, powersport dealers, recreational vehicle dealers, and marine dealers; and home improvement and solar energy installation loans through contractors and installers. The Wealth & Asset Management segment provides various wealth management services for individuals, companies, and not-for-profit organizations. It offers retail brokerage services to individual clients; and broker dealer services to the institutional marketplace. This segment also provides wealth planning, investment management, banking, insurance, and trust and estate services; and advisory services for institutional clients comprising middle market businesses, non-profits, states, and municipalities. The company was founded in 1858 and is headquartered in Cincinnati, Ohio.

Lazard stock logo

Lazard NYSE:LAZ

$45.21 +1.39 (+3.17%)
As of 02:46 PM Eastern

Lazard, Inc., together with its subsidiaries, operates as a financial advisory and asset management firm in North and South America, Europe, the Middle East, Asia, and Australia. It operates in two segments, Financial Advisory and Asset Management. The Financial Advisory segment offers financial advisory services, such as mergers and acquisitions, capital markets, shareholder, sovereign, geopolitical advisory, and other strategic advisory services, as well as restructuring and liability management, and capital raising and placement services. This segment offers its services to corporate, partnership, institutional, government, sovereign, and individual clients to various industry areas, including consumers, financial institutions, healthcare and life sciences, industrials, power and energy/infrastructure, real estate, technology, telecommunication, and media and entertainment. The Asset Management segment offers a range of investment solutions; investment and wealth management services in equity and fixed income strategies; asset allocation strategies; and alternative investments and private equity funds to corporations, public funds, sovereign entities, endowments and foundations, labor funds, financial intermediaries, and private clients. Lazard, Inc. was incorporated in 1848 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.65 +0.49 (+1.80%)
As of 02:40 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.